HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Cited by other online articles Google Scholar Articles by Kenny, A. M. Articles by Raisz, L. G. Articles citing this Article PubMed PubMed Citation Articles by Kenny, A. M. Articles by Raisz, L. G.

Effects of Transdermal Testosterone on Bone and Muscle in Older Men With Low Bioavailable Testosterone Levels

^a Center on Aging, University of Connecticut Health Center, Farmington
^b Lowell P. Weicker General Clinical Research Center, University of Connecticut Health Center, Farmington
^c Braceland Center for Mental Health and Aging, Institute of Living/Hartford Hospital, Hartford, Connecticut

Anne M. Kenny, Center on Aging, MC-5215 University of Connecticut Health Center, Farmington, CT 06030-5215 E-mail: kenny{at}nso1.uchc.edu.

Decision Editor: John E. Morley, MB, BCh

Background. A large proportion of men over 65 years of age have bioavailable testosterone levels below the reference range of young adult men. The impact of this on musculoskeletal health and the potential for improvement in function in this group with testosterone supplementation require investigation.

Methods. Sixty-seven men (mean age 76 ± 4 years, range 65–87) with bioavailable testosterone levels below 4.44 nmol/l (lower limit for adult normal range) were randomized to receive transdermal testosterone (two 2.5-mg patches per day) or placebo patches for 1 year. All men received 500 mg supplemental calcium and 400 IU vitamin D. Outcome measures included sex hormones (testosterone, bioavailable testosterone, sex-hormone binding globulin [SHBG], estradiol, and estrone), bone mineral density (BMD; femoral neck, Ward's triangle, trochanter, lumbar spine, and total body), bone turnover markers, lower extremity muscle strength, percent body fat, lean body mass, hemoglobin, hematocrit, prostate symptoms, and prostate specific antigen (PSA) levels.

Results. Twenty-three men (34%) withdrew from the study; 44 men completed the trial. In these men, bioavailable testosterone levels increased from 3.2 ± 1.2 nmol/l (SD) to 5.6 ± 3.5 nmol/l (p < .002) at 12 months in the testosterone group, whereas no change occurred in the control group. Although there was no change in estradiol levels in either group, estrone levels increased in the testosterone group (103 ± 26 pmol/l to 117 ± 33 pmol/l; p < .017). The testosterone group had a 0.3% gain in femoral neck BMD, whereas the control group lost 1.6% over 12 months (p = .015). No significant changes were seen in markers of bone turnover in either group. Improvements in muscle strength were seen in both groups at 12 months compared with baseline scores. Strength increased 38% (p = .017) in the testosterone group and 27% in the control group (p = .06), with no statistical difference between the groups. In the testosterone group, body fat decreased from 26.3 ± 5.8% to 24.6 ± 6.5% (p = .001), and lean body mass increased from 56.2 ± 5.3 kg to 57.2 ± 5.1 kg (p = .001), whereas body mass did not change. Men receiving testosterone had an increase in PSA from 2.0 ± 1.4 µg/l to 2.6 ± 1.8 µg/l (p = .04), whereas men receiving placebo had an increase in PSA from 1.9 ± 1.0 µg/l to 2.2 ± 1.5 µg/l (p = .09). No significant differences between groups were seen in hemoglobin, hematocrit, symptoms or signs of benign prostate hyperplasia, or PSA levels.

Conclusions. Transdermal testosterone (5 mg/d) prevented bone loss at the femoral neck, decreased body fat, and increased lean body mass in a group of healthy men over age 65 with low bioavailable testosterone levels. In addition, both testosterone and placebo groups demonstrated gains in lower extremity muscle strength, possibly due to the beneficial effects of vitamin D. Testosterone did result in a modest increase in PSA levels but resulted in no change in signs or symptoms of prostate hyperplasia.

This article has been cited by other articles: (Search Google Scholar for Other Citing Articles)

				E. T. Schroeder, A. F. Vallejo, L. Zheng, Y. Stewart, C. Flores, S. Nakao, C. Martinez, and F. R. Sattler Six-Week Improvements in Muscle Mass and Strength During Androgen Therapy in Older Men J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2005; 60(12): 1586 - 1592. [Abstract] [Full Text] [PDF]

				P. Szulc, F. Duboeuf, F. Marchand, and P. D Delmas Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study Am. J. Clinical Nutrition, August 1, 2004; 80(2): 496 - 503. [Abstract] [Full Text] [PDF]

				D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg, R. Bouillon, and C. Ohlsson Androgens and Bone Endocr. Rev., June 1, 2004; 25(3): 389 - 425. [Abstract] [Full Text] [PDF]

				E. T. Schroeder, L. Zheng, K. E. Yarasheski, D. Qian, Y. Stewart, C. Flores, C. Martinez, M. Terk, and F. R. Sattler Treatment with oxandrolone and the durability of effects in older men J Appl Physiol, March 1, 2004; 96(3): 1055 - 1062. [Abstract] [Full Text] [PDF]

				E. L. Rhoden and A. Morgentaler Risks of Testosterone-Replacement Therapy and Recommendations for Monitoring N. Engl. J. Med., January 29, 2004; 350(5): 482 - 492. [Full Text] [PDF]

				S. Bhasin, W. E. Taylor, R. Singh, J. Artaza, I. Sinha-Hikim, R. Jasuja, H. Choi, and N. F. Gonzalez-Cadavid The Mechanisms of Androgen Effects on Body Composition: Mesenchymal Pluripotent Cell as the Target of Androgen Action J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2003; 58(12): M1103 - 1110. [Abstract] [Full Text] [PDF]

				D. R. Thomas The Relationship Between Functional Status and Inflammatory Disease in Older Adults J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2003; 58(11): M995 - 998. [Full Text] [PDF]

				S. Bhasin Testosterone Supplementation for Aging-Associated Sarcopenia J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2003; 58(11): M1002 - 1008. [Abstract] [Full Text] [PDF]

				J. E. Morley Editorial: Sarcopenia Revisited J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2003; 58(10): M909 - 910. [Full Text] [PDF]

				M.-M. G. Wilson and J. E. Morley Invited Review: Aging and energy balance J Appl Physiol, October 1, 2003; 95(4): 1728 - 1736. [Abstract] [Full Text] [PDF]

				J. E. Morley Editorial. Mobility Performance: A High-Tech Test for Geriatricians J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2003; 58(8): M712 - 714. [Full Text] [PDF]

				G. A. Wittert, I. M. Chapman, M. T. Haren, S. Mackintosh, P. Coates, and J. E. Morley Oral Testosterone Supplementation Increases Muscle and Decreases Fat Mass in Healthy Elderly Males With Low-Normal Gonadal Status J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2003; 58(7): M618 - 625. [Abstract] [Full Text] [PDF]

				J. E. Morley The Need for a Men's Health Initiative J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2003; 58(7): M614 - 617. [Full Text] [PDF]

				I. Sinha-Hikim, S. M. Roth, M. I. Lee, and S. Bhasin Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E197 - 205. [Abstract] [Full Text] [PDF]

				S. Bhasin, A. B. Singh, R. P. Mac, B. Carter, M. I. Lee, and G. R. Cunningham Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan J Androl, May 1, 2003; 24(3): 299 - 311. [Full Text] [PDF]

				L. J. Woodhouse, S. Reisz-Porszasz, M. Javanbakht, T. W. Storer, M. Lee, H. Zerounian, and S. Bhasin Development of models to predict anabolic response to testosterone administration in healthy young men Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E1009 - 1017. [Abstract] [Full Text] [PDF]

				S. H. Tariq MD KNOWLEDGE ABOUT LOW TESTOSTERONE IN OLDER MEN J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2003; 58(4): M382 - 383. [Full Text] [PDF]

				H. T. Blumenthal The Aging-Disease Dichotomy: True or False? J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2003; 58(2): M138 - 145. [Full Text] [PDF]

				J. E. Morley Anorexia and Weight Loss in Older Persons J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2003; 58(2): M131 - 137. [Full Text] [PDF]

				J. E. Morley Editorial: Hot Topics in Geriatrics J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2003; 58(1): M30 - 36. [Full Text] [PDF]

				E. T. Schroeder, A. Singh, S. Bhasin, T. W. Storer, C. Azen, T. Davidson, C. Martinez, I. Sinha-Hikim, S. V. Jaque, M. Terk, and F. R. Sattler Effects of an oral androgen on muscle and metabolism in older, community-dwelling men Am J Physiol Endocrinol Metab, January 1, 2003; 284(1): E120 - 128. [Abstract] [Full Text] [PDF]

				M. Iannuzzi-Sucich, K. M. Prestwood, and A. M. Kenny Prevalence of Sarcopenia and Predictors of Skeletal Muscle Mass in Healthy, Older Men and Women J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2002; 57(12): M772 - 777. [Abstract] [Full Text] [PDF]

				J. E. Morley Editorial: Citations, Impact Factor, and the Journal J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2002; 57(12): M765 - 769. [Full Text] [PDF]

				J. K. Anderson, S. Faulkner, C. Cranor, J. Briley, F. Gevirtz, and S. Roberts Andropause: Knowledge and Perceptions Among the General Public and Health Care Professionals J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2002; 57(12): M793 - 796. [Abstract] [Full Text] [PDF]

				J. E. Morley, H. M. Perry III, and D. K. Miller Editorial: Something About Frailty J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2002; 57(11): M698 - 704. [Full Text] [PDF]

				A. Fisher and J. E. Morley Editorial: Antiaging Medicine: The Good, the Bad, and the Ugly J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2002; 57(10): M636 - 639. [Full Text] [PDF]

				J. E. Morley Editorial: A Fall Is a Major Event in the Life of an Older Person J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2002; 57(8): M492 - 495. [Full Text] [PDF]

				A. M. Kenny, K. M. Prestwood, C. A. Gruman, G. Fabregas, B. Biskup, and G. Mansoor Effects of Transdermal Testosterone on Lipids and Vascular Reactivity in Older Men With Low Bioavailable Testosterone Levels J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2002; 57(7): M460 - 465. [Abstract] [Full Text]

				F. Scopacasa, J.M. Wishart, A.G. Need, M. Horowitz, H.A. Morris, and B.E.C. Nordin Bone Density and Bone-Related Biochemical Variables in Normal Men: A Longitudinal Study J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2002; 57(6): M385 - 391. [Abstract] [Full Text]

				J. E. Morley and J. H. Flaherty Editorial It's Never Too Late: Health Promotion and Illness Prevention in Older Persons J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2002; 57(6): M338 - 342. [Full Text]

				A. M. Kenny, S. Bellantonio, C. A. Gruman, R. D. Acosta, and K. M. Prestwood Effects of Transdermal Testosterone on Cognitive Function and Health Perception in Older Men With Low Bioavailable Testosterone Levels J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2002; 57(5): M321 - 325. [Abstract] [Full Text]

				A. M. Matsumoto Andropause: Clinical Implications of the Decline in Serum Testosterone Levels With Aging in Men J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2002; 57(2): M76 - 99. [Full Text]

				J. E. Morley Editorial: Drugs, Aging, and the Future J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2002; 57(1): M2 - 6. [Full Text] [PDF]

				J. E. Morley Editorial: Andropause: Is It Time for the Geriatrician to Treat It? J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2001; 56(5): 263M - 265. [Full Text]